Health Condition 1: G439- Migraine, unspecified
Conditions
Interventions
Intervention1: Habb-e-Mujarrib: 1 gm pills to be taken orally twice daily with water for 12 weeks
Control Intervention1: NIL: NIL
Sponsors
Central Council for Research in Unani Medicine CCRUM New Delhi
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients of either gender in the age group 18- 65 years 2. Primary diagnosis of Migraine without aura by ICHD-3 beta as follows: A. At least five attacks fulfilling criteria B–D. B. Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated). C. Headache has at least two of the following four characteristics: Unilateral location Pulsating quality Moderate or severe pain intensity Aggravation by or causing avoidance of routine physical activity (e.g. walking or climbing stairs). D. During headache at least one of the following: Nausea and/or vomiting. Photophobia and phono phobia. E. Not better accounted for by another ICHD-3 diagnosis
Exclusion criteria
Exclusion criteria: 1. Known case of any structural brain abnormalities 2. Known case of Ocular disease 3. History of Ischemic stroke 4. Any disease involving sinus e.g. Rhinosinusitis 5. Systemic illness requiring long term treatment 6. Known cases of Chronic kidney & liver disease 7. Known cases of Psychiatric illness 8. Difficulty distinguishing migraine headache from other headaches 9. Known cases of Epilepsy and other neurological disorders 10. History of alcohol and drug abuse. 11. Pregnancy & lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The efficacy of the study drug will be assessed on the basis of clinical parameters based on grading of symptoms, scoring of MIDAS and any change in rescue medication pattern.Timepoint: At baseline and at every two weeks till the completion of the trial i.e. upto 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Haematological & biochemical assessment for safety assessment i.e. CBC, LFT, KFT, Urine Routine & microscopic examinationTimepoint: At baseline and at the end of treatment i.e. 12 weeks | — |
Countries
India
Contacts
Public ContactDr Pradeep Kumar
Central Council for Research in Unani Medicine (CCRUM)
Outcome results
None listed